NASH: regulatory considerations for clinical drug development and U.S. FDA approval
Brian E. Harvey
Topics & Concepts
Nonalcoholic steatohepatitisMedicineNonalcoholic fatty liver diseaseCirrhosisClinical trialDrug developmentFatty liverChronic liver diseaseDrugPharmacologyBioinformaticsDiseaseIntensive care medicineInternal medicineBiologyLiver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver Disease and Transplantation